RDY:NYSE
Dr. Reddy's Laboratories
12,75 USD
arrow_downward
-0,16%(-0,020) 1G
12,75 USD
0,00% (0,00)
bedtimeAfter Hours
Chiusura: 14 ott, 16:00:05 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per RDY in corso…
Apertura
12,70 USD
Massimo
12,94 USD
Minimo
12,65 USD
Cap. mercato
10,77 Mld
Vol. medio
3,17 Mln
Volume
0,00
Dividendo
0,65%
Dividendo trimestrale
0,02 USD
Data di stacco dividendo
10 lug 2026
Rapporto P/E
30,58
Max 52 sett.
15,67 USD
Min 52 sett.
11,36 USD
Utili per azione
0,42 USD
Beta
0,30
Azioni in circolazione
834,64 Mln
N. di dipendenti
28K
Apertura
12,70 USD
Massimo
12,94 USD
Minimo
12,65 USD
Cap. mercato
10,77 Mld
Vol. medio
3,17 Mln
Volume
0,00
Dividendo
0,65%
Dividendo trimestrale
0,02 USD
Data di stacco dividendo
10 lug 2026
Rapporto P/E
30,58
Max 52 sett.
15,67 USD
Min 52 sett.
11,36 USD
Utili per azione
0,42 USD
Beta
0,30
Azioni in circolazione
834,64 Mln
N. di dipendenti
28K
Articoli giornalistici
Da fonti web e partner giornalistici
MarketBeat
·
3 ore fa
Dr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?
Equitypandit
·
6 ore fa
Stocks in Focus: Dr Reddy’s Lab, Enviro Infra, and Others
Stock Titan
·
17 ore fa
An FDA pre-approval inspection ends with observations at Dr. Reddy’s (RDY) Visakhapatnam plant.
Stock Traders Daily
·
1 giorno fa
Liquidity Mapping Around (RDY) Price Events
Profilo
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Informazioni su Dr. Reddy's Laboratories
CEOErez Israeli
Dipendenti27,5K
Data di fondazione1984
SedeHyderabad, Andhra Pradesh, India
Settore-
Sito webdrreddys.com